Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathway

Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147:258–267 van Pesch V, Lanaya H, Renauld J-C, Michiels T (2004) Characterization of the murine alpha interferon gene family. J Virol 78:8219–8228. doi:10.1128/JVI.78.15.8219-8228.2004 Uzé G, Schreiber G, Piehler J, Pellegrini S (2007) The receptor of the type I interferon family. In: Pitha PM (ed) Interferon 50th anniv. Springer, Berlin, pp 71–95 Müller U, Steinhoff U, Reis LF et al (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918–1921 Jouanguy E, Zhang S-Y, Chapgier A et al (2007) Human primary immunodeficiencies of type I interferons. Biochimie 89:878–883. doi:10.1016/j.biochi.2007.04.016 Simmons DP, Wearsch PA, Canaday DH et al (2012) Type I interferon drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J Immunol Baltim Md 188:3116–3126. doi:10.4049/jimmunol.1101313 Cella M, Salio M, Sakakibara Y et al (1999) Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 189:821–829 Castelli JC, Hassel BA, Wood KA et al (1997) A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 186:967–972 Garland Science—Book: Janeway’s Immunobiology + 7. http://www.garlandscience.com/product/isbn/0815341237. Accessed 7 Sept 2016 Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA (2011) Pattern recognition receptors and the innate immune response to viral infection. Viruses 3:920–940. doi:10.3390/v3060920 Xagorari A, Chlichlia K (2008) Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J 2:49–59. doi:10.2174/1874285800802010049 Grandvaux N, Servant MJ, tenOever B et al (2002) Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol 76:5532–5539 Tamura T, Yanai H, Savitsky D, Taniguchi T (2008) The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26:535–584. doi:10.1146/annurev.immunol.26.021607.090400 Gack MU (2014) Mechanisms of RIG-I-like receptor activation and manipulation by viral pathogens. J Virol 88:5213–5216. doi:10.1128/JVI.03370-13 Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375–386. doi:10.1038/nri1604 Levy DE, Marié I, Smith E, Prakash A (2002) Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 22:87–93. doi:10.1089/107999002753452692 Hertzog PJ, Williams BRG (2013) Fine tuning type I interferon responses. Cytokine Growth Factor Rev 24:217–225. doi:10.1016/j.cytogfr.2013.04.002 Aaronson DS, Horvath CM (2002) A road map for those who don’t know JAK-STAT. Science 296:1653–1655. doi:10.1126/science.1071545 Levy DE, Darnell JE (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651–662. doi:10.1038/nrm909 Decker T, Müller M, Stockinger S (2005) The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5:675–687. doi:10.1038/nri1684 Brooks AJ, Dai W, O’Mara ML et al (2014) Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344:1249783. doi:10.1126/science.1249783 Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513–545. doi:10.1146/annurev-immunol-032713-120231 de Veer MJ, Holko M, Frevel M et al (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69:912–920 Schoggins JW, Rice CM (2011) Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1:519–525. doi:10.1016/j.coviro.2011.10.008 Gao S, von der Malsburg A, Paeschke S et al (2010) Structural basis of oligomerization in the stalk region of dynamin-like MxA. Nature 465:502–506. doi:10.1038/nature08972 Xiao H, Killip MJ, Staeheli P et al (2013) The human interferon-induced MxA protein inhibits early stages of influenza A virus infection by retaining the incoming viral genome in the cytoplasm. J Virol. doi:10.1128/JVI.02220-13 Klockow B, Tichelaar W, Madden DR et al (2002) The dynamin A ring complex: molecular organization and nucleotide-dependent conformational changes. EMBO J 21:240–250. doi:10.1093/emboj/21.3.240 Haller O, Kochs G (2011) Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 31:79–87. doi:10.1089/jir.2010.0076 Kane M, Yadav SS, Bitzegeio J et al (2013) MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502:563–566. doi:10.1038/nature12653 Goujon C, Moncorgé O, Bauby H et al (2013) Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502:559–562. doi:10.1038/nature12542 Brass AL, Huang I-C, Benita Y et al (2009) The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139:1243–1254. doi:10.1016/j.cell.2009.12.017 Wilkins C, Woodward J, Lau DT-Y et al (2013) IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatol Baltim Md 57:461–469. doi:10.1002/hep.26066 Lu J, Pan Q, Rong L et al (2011) The IFITM proteins inhibit HIV-1 infection. J Virol 85:2126–2137. doi:10.1128/JVI.01531-10 Feeley EM, Sims JS, John SP et al (2011) IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog 7:e1002337. doi:10.1371/journal.ppat.1002337 Everitt AR, Clare S, Pertel T et al (2012) IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519–523. doi:10.1038/nature10921 Wang Y, Pan Q, Ding S et al (2017) The V3-loop of HIV-1 Env determines viral susceptibility to IFITM3 impairment of viral infectivity. J Virol. doi:10.1128/JVI.02441-16 Ozato K, Shin D-M, Chang T-H, Morse HC (2008) TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8:849–860. doi:10.1038/nri2413 Stremlau M, Owens CM, Perron MJ et al (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848–853. doi:10.1038/nature02343 Diaz-Griffero F (2011) Caging the beast: TRIM5α binding to the HIV-1 core. Viruses 3:423–428. doi:10.3390/v3050423 Ganser-Pornillos BK, Chandrasekaran V, Pornillos O et al (2011) Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci USA 108:534–539. doi:10.1073/pnas.1013426108 Towers GJ (2007) The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4:40. doi:10.1186/1742-4690-4-40 Rold CJ, Aiken C (2008) Proteasomal degradation of TRIM5α during retrovirus restriction. PLoS Pathog 4:e1000074. doi:10.1371/journal.ppat.1000074 Singh R, Gaiha G, Werner L et al (2011) Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol 85:208–216. doi:10.1128/JVI.01810-10 Hattlmann CJ, Kelly JN, Barr SD (2012) TRIM22: a diverse and dynamic antiviral protein. Mol Biol Int 2012:e153415. doi:10.1155/2012/153415 Gao B, Duan Z, Xu W, Xiong S (2009) Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatol Baltim Md 50:424–433. doi:10.1002/hep.23011 Di Pietro A, Kajaste-Rudnitski A, Oteiza A et al (2013) TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol 87:4523–4533. doi:10.1128/JVI.02548-12 Zhao C, Collins M, Hsiang T-Y, Krug RM (2013) Interferon-induced ISG15 pathway: an ongoing virus–host battle. Trends Microbiol 21:181–186. doi:10.1016/j.tim.2013.01.005 Shi H-X, Yang K, Liu X et al (2010) Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol 30:2424–2436. doi:10.1128/MCB.01466-09 Lenschow DJ, Lai C, Frias-Staheli N et al (2007) IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 104:1371–1376. doi:10.1073/pnas.0607038104 Bogunovic D, Byun M, Durfee LA et al (2012) Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science 337:1684–1688. doi:10.1126/science.1224026 Speer SD, Li Z, Buta S et al (2016) ISG15 deficiency and increased viral resistance in humans but not mice. Nat Commun. doi:10.1038/ncomms11496 Hovanessian AG, Justesen J (2007) The human 2′-5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie 89:779–788. doi:10.1016/j.biochi.2007.02.003 Clemens MJ, Vaquero CM (1978) Inhibition of protein synthesis by double-stranded RNA in reticulocyte lysates: evidence for activation of an endoribonuclease. Biochem Biophys Res Commun 83:59–68 Zhou A, Paranjape J, Brown TL et al (1997) Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J 16:6355–6363. doi:10.1093/emboj/16.21.6355 Bonnevie-Nielsen V, Field LL, Lu S et al (2005) Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 76:623–633. doi:10.1086/429391 Kristiansen H, Scherer CA, McVean M et al (2010) Extracellular 2′-5′ oligoadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity. J Virol 84:11898–11904. doi:10.1128/JVI.01003-10 Choi UY, Kang J-S, Hwang YS, Kim Y-J (2015) Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases. Exp Mol Med 47:e144. doi:10.1038/emm.2014.110 Zhu J, Zhang Y, Ghosh A et al (2014) Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity 40:936–948. doi:10.1016/j.immuni.2014.05.007 Lee MS, Kim B, Oh GT, Kim Y-J (2013) OASL1 inhibits translation of the type I interferon-regulating transcription factor IRF7. Nat Immunol 14:346–355. doi:10.1038/ni.2535 Meurs E, Chong K, Galabru J et al (1990) Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62:379–390 Roberts WK, Hovanessian A, Brown RE et al (1976) Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 264:477–480. doi:10.1038/264477a0 Balachandran S, Roberts PC, Brown LE et al (2000) Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13:129–141 Zhang L, Alter HJ, Wang H et al (2013) The modulation of hepatitis C virus 1a replication by PKR is dependent on NF-κB mediated interferon beta response in Huh7.5.1 cells. Virology 438:28–36. doi:10.1016/j.virol.2013.01.015 Jha BK, Polyakova I, Kessler P et al (2011) Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. J Biol Chem 286:26319–26326. doi:10.1074/jbc.M111.253443 de Wilde AH, Wannee KF, Scholte FEM et al (2015) A kinome-wide small interfering RNA screen identifies proviral and antiviral host factors in severe acute respiratory syndrome coronavirus replication, including double-stranded RNA-activated protein kinase and early secretory pathway proteins. J Virol 89:8318–8333. doi:10.1128/JVI.01029-15 Wang X, Hinson ER, Cresswell P (2007) The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe 2:96–105. doi:10.1016/j.chom.2007.06.009 Helbig KJ, Eyre NS, Yip E et al (2011) The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatol Baltim Md 54:1506–1517. doi:10.1002/hep.24542 Perez-Caballero D, Zang T, Ebrahimi A et al (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499–511. doi:10.1016/j.cell.2009.08.039 Barrett BS, Smith DS, Li SX et al (2012) A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog 8:e1002596. doi:10.1371/journal.ppat.1002596 Jouvenet N, Neil SJD, Zhadina M et al (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83:1837–1844. doi:10.1128/JVI.02211-08 Sakuma T, Noda T, Urata S et al (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83:2382–2385. doi:10.1128/JVI.01607-08 Mansouri M, Viswanathan K, Douglas JL et al (2009) Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi’s sarcoma-associated herpesvirus. J Virol 83:9672–9681. doi:10.1128/JVI.00597-09 Arias JF, Heyer LN, von Bredow B et al (2014) Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci USA 111:6425–6430. doi:10.1073/pnas.1321507111 Manns MP, Wedemeyer H, Cornberg M (2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350–1359. doi:10.1136/gut.2005.076646 Piganis RAR, De Weerd NA, Gould JA et al (2011) Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 286:33811–33818. doi:10.1074/jbc.M111.270207 Tamiya T, Kashiwagi I, Takahashi R et al (2011) Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways. Arterioscler Thromb Vasc Biol 31:980–985. doi:10.1161/ATVBAHA.110.207464 Vlotides G, Sörensen AS, Kopp F et al (2004) SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 320:1007–1014. doi:10.1016/j.bbrc.2004.06.051 Akhtar LN, Benveniste EN (2011) Viral exploitation of host SOCS protein functions. J Virol 85:1912–1921. doi:10.1128/JVI.01857-10 Malakhov MP, Malakhova OA, Kim KI et al (2002) UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 277:9976–9981. doi:10.1074/jbc.M109078200 Ritchie KJ, Hahn CS, Kim KI et al (2004) Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 10:1374–1378. doi:10.1038/nm1133 François-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B et al (2011) USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLOS One 6:22200. doi:10.1371/journal.pone.0022200 Chen L, Borozan I, Feld J et al (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128:1437–1444 Borden EC, Sen GC, Uze G et al (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975–990. doi:10.1038/nrd2422 Haas DW, Lavelle J, Nadler JP et al (2000) A randomized trial of interferon alpha therapy for HIV type 1 infection. AIDS Res Hum Retroviruses 16:183–190. doi:10.1089/088922200309278 Zeuzem S, Berg T, Moeller B et al (2009) Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 16:75–90. doi:10.1111/j.1365-2893.2008.01012.x Stevenson NJ, Bourke NM, Ryan EJ et al (2013) Hepatitis C virus targets the interferon-α JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes. FEBS Lett 587:1571–1578. doi:10.1016/j.febslet.2013.03.041